Icon Advisers Inc. Co. reduced its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 58.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,700 shares of the specialty pharmaceutical company’s stock after selling 12,000 shares during the quarter. Icon Advisers Inc. Co. owned 0.07% of ANI Pharmaceuticals worth $407,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the stock. Teachers Advisors LLC raised its stake in ANI Pharmaceuticals by 11.9% during the 2nd quarter. Teachers Advisors LLC now owns 14,098 shares of the specialty pharmaceutical company’s stock valued at $660,000 after purchasing an additional 1,494 shares during the last quarter. Alliancebernstein L.P. raised its stake in ANI Pharmaceuticals by 32.7% during the 2nd quarter. Alliancebernstein L.P. now owns 10,550 shares of the specialty pharmaceutical company’s stock valued at $494,000 after purchasing an additional 2,600 shares during the last quarter. Wells Fargo & Company MN raised its stake in ANI Pharmaceuticals by 81.8% during the 2nd quarter. Wells Fargo & Company MN now owns 16,058 shares of the specialty pharmaceutical company’s stock valued at $752,000 after purchasing an additional 7,226 shares during the last quarter. Hikari Power Ltd raised its stake in ANI Pharmaceuticals by 142.6% during the 2nd quarter. Hikari Power Ltd now owns 12,130 shares of the specialty pharmaceutical company’s stock valued at $568,000 after purchasing an additional 7,130 shares during the last quarter. Finally, Mark Sheptoff Financial Planning LLC raised its stake in ANI Pharmaceuticals by 9.9% during the 2nd quarter. Mark Sheptoff Financial Planning LLC now owns 5,550 shares of the specialty pharmaceutical company’s stock valued at $260,000 after purchasing an additional 500 shares during the last quarter. Hedge funds and other institutional investors own 55.86% of the company’s stock.

ANIP has been the subject of a number of recent research reports. BidaskClub cut shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Canaccord Genuity reiterated a “buy” rating and set a $60.00 target price on shares of ANI Pharmaceuticals in a research report on Wednesday, August 9th. ValuEngine cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Zacks Investment Research upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, July 5th. Finally, Guggenheim reiterated a “buy” rating and set a $80.00 target price on shares of ANI Pharmaceuticals in a research report on Tuesday, July 4th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company has an average rating of “Hold” and an average price target of $65.33.

ANI Pharmaceuticals, Inc. (ANIP) opened at 49.83 on Tuesday. ANI Pharmaceuticals, Inc. has a 52 week low of $42.23 and a 52 week high of $69.85. The stock has a 50 day moving average of $46.74 and a 200 day moving average of $47.75. The company has a market cap of $579.92 million, a price-to-earnings ratio of 109.04 and a beta of 3.10.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported $0.98 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.79 by $0.19. ANI Pharmaceuticals had a return on equity of 22.70% and a net margin of 3.35%. The business had revenue of $44.80 million for the quarter, compared to the consensus estimate of $43.20 million. During the same period in the previous year, the company posted $1.11 earnings per share. The company’s revenue for the quarter was up 43.0% compared to the same quarter last year. Equities research analysts predict that ANI Pharmaceuticals, Inc. will post $3.84 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This story was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/09/19/ani-pharmaceuticals-inc-anip-shares-sold-by-icon-advisers-inc-co.html.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Institutional Ownership by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Stock Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.